pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 9·1 min read
save

New OpenEvidence study shows it outperforms general-purpose LLMs in health-tech research

Jul 9, 2026·read at STAT ↗Positive

A recent study funded by OpenEvidence compared its platform to general-purpose large language models (LLMs) in health technology research and concluded that OpenEvidence delivered more accurate and reliable results.

The findings directly challenge an earlier high-profile study released weeks before, which had suggested LLMs were on par with specialized tools.

In the same newsletter, Dexcom announced FDA clearance for its continuous glucose monitor to be used in children, expanding its pediatric market.

An additional survey of American Medical Association members highlighted growing interest in wearable devices among clinicians.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: OpenEvidence backs study that finds it beats LLMs”

read at STAT ↗
446 words · retrieved Jul 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Cardiology2Psychiatry & CNS2GLP-1 receptor

related stories

  • Sep 21Are healthcare systems really ready for GLP-1s?BioPharma Dive
  • Sep 8An administrative gap delays access to new pancreatic cancer treatmentSTAT
  • Sep 1From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s AppleFierce Biotech
  • Jul 28After PCOS became PMOS, there’s hope for new awareness among Black and Latina womenSTAT
  • Jul 20HHS vaccine committee quietly gets new charterSTAT